{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:45:35Z","timestamp":1789469135878,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":70,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital, Linkou","doi-asserted-by":"publisher","award":["CORPG3G0821"],"award-info":[{"award-number":["CORPG3G0821"]}],"id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07134-6","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T04:45:28Z","timestamp":1781844328000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["\u03b22-microglobulin is superior to lactate dehydrogenase and bulky disease for risk stratification in diffuse large B-cell lymphoma patients with IPI 1\u20132"],"prefix":"10.1007","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8451-0304","authenticated-orcid":false,"given":"Hung","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Shin","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Chung","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tung-Liang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiao-Wen","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsuan-Jen","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Jiun","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuen-Chin","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning-Chun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"issue":"14","key":"7134_CR1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/nejm199309303291402","volume":"329","author":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma","year":"1993","unstructured":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma (1993) N Engl J Med 329(14):987\u2013994. https:\/\/doi.org\/10.1056\/nejm199309303291402","journal-title":"N Engl J Med"},{"issue":"23","key":"7134_CR2","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1182\/blood.2019002729","volume":"135","author":"AS Ruppert","year":"2020","unstructured":"Ruppert AS, Dixon JG, Salles G, Wall A, Cunningham D, Poeschel V, Haioun C, Tilly H, Ghesquieres H, Ziepert M, Flament J, Flowers C, Shi Q, Schmitz N (2020) International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood 135(23):2041\u20132048. https:\/\/doi.org\/10.1182\/blood.2019002729","journal-title":"Blood"},{"key":"7134_CR3","doi-asserted-by":"publisher","unstructured":"Maurer MJWT, Habermann TM et al (2023) The presence of bulky disease and\/or very high LDH defines a high-risk subset of IPI 1\u20132 for eligibility in clinical trials of newly diagnosed aggressive B-cell lymphoma. Blood 142 (Supplement 1):[abstract 4512]. https:\/\/doi.org\/10.1182\/blood-2023-187350","DOI":"10.1182\/blood-2023-187350"},{"key":"7134_CR4","doi-asserted-by":"crossref","unstructured":"Vassilakopoulos TP, Arapaki MP, Apostolopoulou C, Verrou E, Kalpadakis CH, Piperidou A, Liaskas A, Sachanas S, Triantafyllou T, Bitsani A, Dimou M, Ioakeim MA, Siakantaris M, Pangalis G, Katodritou E, Angelopoulou M, Panayiotidis P, Pappa V, Papageorgiou SG (2024) Disease Bulk and\/or Very High LDH As Adverse Factors in IPI 1\u20132 Diffuse Large B-Cell Lymphoma (DLBCL): A Hellenic Database Validation of the LEO Cohort. Blood 144 (Supplement 1):[Abstract no. 624]","DOI":"10.1182\/blood-2024-210585"},{"issue":"7","key":"7134_CR5","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1007\/s10238-023-01061-w","volume":"23","author":"NC Chen","year":"2023","unstructured":"Chen NC, Chang H, Kao HW, Ou CW, Kuo MC, Wang PN, Lin TL, Wu JH, Hung YS, Su YJ, Ong YC, Shih HJ (2023) Beta2-microglobulin is a valuable marker and identifies a poor-prognosis subgroup among intermediate-risk patients with diffuse large B cell lymphoma. Clin Exp Med 23(7):3759\u20133766. https:\/\/doi.org\/10.1007\/s10238-023-01061-w","journal-title":"Clin Exp Med"},{"issue":"4","key":"7134_CR6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trn\u011bn\u00fd M, Sharman JP, Herbaux C, Burke JM, Matasar M, Rai S, Izutsu K, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Greil R, Mykhalska L, Bergua-Burgu\u00e9s JM, Cheung MC, Pinto A, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Hirata J, Jiang Y, Yan M, Lee C, Flowers CR, Salles G (2022) Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med 386(4):351\u2013363. https:\/\/doi.org\/10.1056\/NEJMoa2115304","journal-title":"N Engl J Med"},{"issue":"6","key":"7134_CR7","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1111\/bjh.20129","volume":"206","author":"S Chaganti","year":"2025","unstructured":"Chaganti S, Fox CP, Maybury BD, Burton C, Barrington SF, Illidge T, Kalakonda N, Eyre TA, McKay P, Kuhnl A, Cwynarski K, Davies AJ (2025) Management of relapsed or refractory large B-cell lymphoma: A British Society for Haematology Guideline. Br J Haematol 206(6):1593\u20131603. https:\/\/doi.org\/10.1111\/bjh.20129","journal-title":"Br J Haematol"},{"issue":"1","key":"7134_CR8","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13045-025-01702-5","volume":"18","author":"AM Bock","year":"2025","unstructured":"Bock AM, Epperla N (2025) Therapeutic landscape of primary refractory and relapsed diffuse large B-cell lymphoma: Recent advances and emerging therapies. J Hematol Oncol 18(1):68. https:\/\/doi.org\/10.1186\/s13045-025-01702-5","journal-title":"J Hematol Oncol"},{"issue":"10","key":"7134_CR9","doi-asserted-by":"publisher","first-page":"4897","DOI":"10.1007\/s00277-025-06686-3","volume":"104","author":"A Duminuco","year":"2025","unstructured":"Duminuco A, Scarso S, Del Fabro V, Caruso LA, Stanzione G, Di Raimondo F, Palumbo GA, Vetro C (2025) Diffuse large B-cell lymphoma in the new era: prognostic tools for mapping risk. Ann Hematol 104(10):4897\u20134911. https:\/\/doi.org\/10.1007\/s00277-025-06686-3","journal-title":"Ann Hematol"},{"issue":"15","key":"7134_CR10","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, Roulland S, Kasbekar M, Young RM, Shaffer AL, Hodson DJ, Xiao W, Yu X, Yang Y, Zhao H, Xu W, Liu X, Zhou B, Du W, Chan WC, Jaffe ES, Gascoyne RD, Connors JM, Campo E, Lopez-Guillermo A, Rosenwald A, Ott G, Delabie J, Rimsza LM, Wei TK, Zelenetz K, Leonard AD, Bartlett JP, Tran NL, Shetty B, Zhao J, Soppet Y, Pittaluga DR, Wilson S, Staudt WH LM (2018) Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med 378(15):1396\u20131407. https:\/\/doi.org\/10.1056\/NEJMoa1801445","journal-title":"N Engl J Med"},{"issue":"5","key":"7134_CR11","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, Lawrence MS, Roemer MGM, Li AJ, Ziepert M, Staiger AM, Wala JA, Ducar MD, Leshchiner I, Rheinbay E, Taylor-Weiner A, Coughlin CA, Hess JM, Pedamallu CS, Livitz D, Rosebrock D, Rosenberg M, Tracy AA, Horn H, van Hummelen P, Feldman AL, Link BK, Novak AJ, Cerhan JR, Habermann TM, Siebert R, Rosenwald A, Thorner AR, Meyerson ML, Golub TR, Beroukhim R, Wulf GG, Ott G, Rodig SJ, Monti S, Neuberg DS, Loeffler M, Pfreundschuh M, Tr\u00fcmper L, Getz G, Shipp MA (2018) Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 24(5):679\u2013690. https:\/\/doi.org\/10.1038\/s41591-018-0016-8","journal-title":"Nat Med"},{"issue":"4","key":"7134_CR12","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1111\/bjh.17811","volume":"196","author":"RD Morin","year":"2022","unstructured":"Morin RD, Arthur SE, Hodson DJ (2022) Molecular profiling in diffuse large B-cell lymphoma: why so many types of subtypes? Br J Haematol 196(4):814\u2013829. https:\/\/doi.org\/10.1111\/bjh.17811","journal-title":"Br J Haematol"},{"issue":"1","key":"7134_CR13","doi-asserted-by":"publisher","first-page":"e70006","DOI":"10.1002\/hon.70006","volume":"43","author":"AM Bock","year":"2025","unstructured":"Bock AM, Wenzl K, Novak JP, Stokes ME, Hopper MA, Krull JE, Dropik AR, Sarangi V, Ortiz M, Stong N, Huang CC, Maurer MJ, King RL, Farooq U, Wang Y, Witzig TE, Ansell SM, Habermann TM, Cerhan JR, Gandhi AK, Nowakowski G, Novak AJ (2025) Molecular Features of Diffuse Large B-Cell Lymphoma Associated With Primary Treatment Resistance. Hematol Oncol 43(1):e70006. https:\/\/doi.org\/10.1002\/hon.70006","journal-title":"Hematol Oncol"},{"issue":"6769","key":"7134_CR14","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr., Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403(6769):503\u2013511. https:\/\/doi.org\/10.1038\/35000501","journal-title":"Nature"},{"issue":"1","key":"7134_CR15","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, M\u00fcller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103(1):275\u2013282. https:\/\/doi.org\/10.1182\/blood-2003-05-1545","journal-title":"Blood"},{"issue":"12","key":"7134_CR16","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1200\/jco.2014.57.7080","volume":"33","author":"K Dybk\u00e6r","year":"2015","unstructured":"Dybk\u00e6r K, B\u00f8gsted M, Falgreen S, B\u00f8dker JS, Kjeldsen MK, Schmitz A, Bilgrau AE, Xu-Monette ZY, Li L, Bergkvist KS, Laursen MB, Rodrigo-Domingo M, Marques SC, Rasmussen SB, Nyegaard M, Gaihede M, M\u00f8ller MB, Samworth RJ, Shah RD, Johansen P, El-Galaly TC, Young KH, Johnsen HE (2015) Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis. J Clin oncology: official J Am Soc Clin Oncol 33(12):1379\u20131388. https:\/\/doi.org\/10.1200\/jco.2014.57.7080","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"8","key":"7134_CR17","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1182\/blood-2010-09-297879","volume":"117","author":"SM Aukema","year":"2011","unstructured":"Aukema SM, Siebert R, Schuuring E, van Imhoff GW, Kluin-Nelemans HC, Boerma EJ, Kluin PM (2011) Double-hit B-cell lymphomas. Blood 117(8):2319\u20132331. https:\/\/doi.org\/10.1182\/blood-2010-09-297879","journal-title":"Blood"},{"issue":"7","key":"7134_CR18","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, Bhagat G, Borges AM, Boyer D, Calaminici M, Chadburn A, Chan JKC, Cheuk W, Chng WJ, Choi JK, Chuang SS, Coupland SE, Czader M, Dave SS, de Jong D, Du MQ, Elenitoba-Johnson KS, Ferry J, Geyer J, Gratzinger D, Guitart J, Gujral S, Harris M, Harrison CJ, Hartmann S, Hochhaus A, Jansen PM, Karube K, Kempf W, Khoury J, Kimura H, Klapper W, Kovach AE, Kumar S, Lazar AJ, Lazzi S, Leoncini L, Leung N, Leventaki V, Li XQ, Lim MS, Liu WP, Louissaint A Jr., Marcogliese A, Medeiros LJ, Michal M, Miranda RN, Mitteldorf C, Montes-Moreno S, Morice W, Nardi V, Naresh KN, Natkunam Y, Ng SB, Oschlies I, Ott G, Parrens M, Pulitzer M, Rajkumar SV, Rawstron AC, Rech K, Rosenwald A, Said J, Sarkozy C, Sayed S, Saygin C, Schuh A, Sewell W, Siebert R, Sohani AR, Tooze R, Traverse-Glehen A, Vega F, Vergier B, Wechalekar AD, Wood B, Xerri L, Xiao W (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 36(7):1720\u20131748. https:\/\/doi.org\/10.1038\/s41375-022-01620-2","journal-title":"Leukemia"},{"issue":"6","key":"7134_CR19","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/j.1600-0609.2012.01778.x","volume":"88","author":"ZM Li","year":"2012","unstructured":"Li ZM, Huang JJ, Xia Y, Zhu YJ, Zhao W, Wei WX, Jiang WQ, Lin TY, Huang HQ, Guan ZZ (2012) High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy. Eur J Haematol 88(6):510\u2013517. https:\/\/doi.org\/10.1111\/j.1600-0609.2012.01778.x","journal-title":"Eur J Haematol"},{"issue":"2","key":"7134_CR20","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1600-0609.2010.01467.x","volume":"85","author":"DH Yoon","year":"2010","unstructured":"Yoon DH, Choi DR, Ahn HJ, Kim S, Lee DH, Kim SW, Park BH, Yoon SO, Huh J, Lee SW, Suh C (2010) Ki-67 expression as a prognostic factor in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP. Eur J Haematol 85(2):149\u2013157. https:\/\/doi.org\/10.1111\/j.1600-0609.2010.01467.x","journal-title":"Eur J Haematol"},{"issue":"2","key":"7134_CR21","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/bjh.18016","volume":"197","author":"TC El-Galaly","year":"2022","unstructured":"El-Galaly TC, Villa D, Cheah CY, Gormsen LC (2022) Pre-treatment total metabolic tumour volumes in lymphoma: Does quantity matter? Br J Haematol 197(2):139\u2013155. https:\/\/doi.org\/10.1111\/bjh.18016","journal-title":"Br J Haematol"},{"issue":"3","key":"7134_CR22","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/annonc\/mdq403","volume":"22","author":"M Picardi","year":"2011","unstructured":"Picardi M, Soricelli A, Grimaldi F, Nicolai E, Gallamini A, Pane F (2011) Fused FDG-PET\/contrast-enhanced CT detects occult subdiaphragmatic involvement of Hodgkin\u2019s lymphoma thereby identifying patients requiring six cycles of anthracycline-containing chemotherapy and consolidation radiation of spleen. Ann Oncol 22(3):671\u2013680. https:\/\/doi.org\/10.1093\/annonc\/mdq403","journal-title":"Ann Oncol"},{"issue":"5","key":"7134_CR23","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","volume":"109","author":"LH Sehn","year":"2007","unstructured":"Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, Gascoyne RD, Connors JM (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109(5):1857\u20131861. https:\/\/doi.org\/10.1182\/blood-2006-08-038257","journal-title":"Blood"},{"issue":"6","key":"7134_CR24","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","volume":"123","author":"Z Zhou","year":"2014","unstructured":"Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, Vanderplas A, Zelenetz AD, Abel GA, Rodriguez MA, Nademanee A, Kaminski MS, Czuczman MS, Millenson M, Niland J, Gascoyne RD, Connors JM, Friedberg JW, Winter JN (2014) An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 123(6):837\u2013842. https:\/\/doi.org\/10.1182\/blood-2013-09-524108","journal-title":"Blood"},{"issue":"1","key":"7134_CR25","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/cam4.1271","volume":"7","author":"J Biccler","year":"2018","unstructured":"Biccler J, Eloranta S, de Nully Brown P, Frederiksen H, Jerkeman M, Smedby KE, B\u00f8gsted M, El-Galaly TC (2018) Simplicity at the cost of predictive accuracy in diffuse large B-cell lymphoma: a critical assessment of the R-IPI, IPI, and NCCN-IPI. Cancer Med 7(1):114\u2013122. https:\/\/doi.org\/10.1002\/cam4.1271","journal-title":"Cancer Med"},{"issue":"1","key":"7134_CR26","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1080\/16078454.2022.2147916","volume":"27","author":"N Warnnissorn","year":"2022","unstructured":"Warnnissorn N, Kanitsap N, Niparuck P, Boonsakan P, Kulalert P, Limvorapitak W, Bhoopat L, Saengboon S, Chantrathammachart P, Puavilai T, Chuncharunee S (2022) External validation and comparison of IPI, R-IPI, and NCCN-IPI in diffuse large B-cell lymphoma patients treated with R-CHOP to predict 2-year progression-free survival. Hematology 27(1):1237\u20131245. https:\/\/doi.org\/10.1080\/16078454.2022.2147916","journal-title":"Hematology"},{"issue":"5","key":"7134_CR27","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/bjh.18348","volume":"198","author":"M Picardi","year":"2022","unstructured":"Picardi M, Giordano C, Pugliese N, Esposito M, Fatigati M, Muriano F, Rascato MG, Della Pepa R, D\u2019Ambrosio A, Vigliar E, Troncone G, Russo D, Mascolo M, Esposito G, Prastaro M, Esposito R, Tocchetti CG, Fonti R, Mainolfi C, Del Vecchio S, Pane F (2022) Liposomal doxorubicin supercharge-containing front-line treatment in patients with advanced-stage diffuse large B-cell lymphoma or classical Hodgkin lymphoma: Preliminary results of a single-centre phase II study. Br J Haematol 198(5):847\u2013860. https:\/\/doi.org\/10.1111\/bjh.18348","journal-title":"Br J Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07134-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07134-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07134-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:42:44Z","timestamp":1789465364000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07134-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":27,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["7134"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07134-6","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"30 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective study was approved by the institutional review board of Chang Gung Medical Foundation (IRB No. 202100653B0). The requirement for informed consent was waived owing to the anonymous nature of the data.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable (waived by institutional review board).","order":2,"name":"Ethics","label":"Patient consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"398"}}